Pregabalin Capsule
Product Images NDC 71610-930

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-930). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0930 30)

Pregabalin 50 mg oral capsules packaging label showing 30 capsules per bottle. The label includes storage instructions to keep between 20-25 degrees Celsius, protects from light and moisture, and includes a warning of possible habit forming. Manufactured by Siegen Pharma Pharmaceuticals, Hauppauge, NY, and repackaged by Aphena Pharma, Cookeville, TN. Marked RX only with NDC 71610-930-30.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin, showing its molecular framework with a carboxyl group (CO2H) and an amino group (NH2) attached to a branched carbon chain.*

FDA Label Image

Figure 1 (Pregabalin 02)

A cumulative distribution plot showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin doses of 25 mg, 100 mg, and 200 mg taken three times a day with placebo, illustrating pain improvement outcomes.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph showing the relationship between percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two lines compare Pregabalin 100 mg three times a day versus placebo, with Pregabalin showing a higher percentage of patient improvement across improvement levels.*

FDA Label Image

Figure 3 (Pregabalin 04)

A graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The chart includes lines representing different Pregabalin dosages (300 mg, 150 mg, 75 mg, taken two times a day) and placebo, comparing their effects on patient pain improvement.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. The graph compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating patient improvement trends across different pain improvement thresholds.*

FDA Label Image

Figure 6 (Pregabalin 07)

Bar chart comparing responder rates (%) in two studies, Study E1 and Study E3, for Pregabalin at various dosages versus placebo. The x-axis shows different dosage groups and placebo, while the y-axis represents responder rates as percentages.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day. The graph compares seizure reduction across four studies (E1 BD, E2 TID, E3 BD, E3 TID) with data points at different doses, illustrating increasing seizure reduction with dose, accompanied by significant p-values.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar graph illustrating responder rates (percentage) for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day, with sample sizes of 93, 103, and 96 respectively. The graph shows increasing responder rates from placebo (22.6%) to the highest dosage (40.6%).*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, illustrating trends of patient improvement over a range of pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin 11)

A survival curve chart depicting the estimated percentage of subjects without LTR over days, comparing Pregabalin versus placebo groups. The vertical axis shows percentage from 0% to 100%, and the horizontal axis indicates days from 0 to 180, with Pregabalin showing higher percentages of subjects without LTR over time compared to placebo.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph comparing the percentage of subjects improved over time from baseline to Week 12 using the 12-Item Brief Occupational Functioning Scale (BOCF). The graph shows two lines: one for Pregabalin and one for Placebo, with the Pregabalin line consistently higher, indicating a greater percentage of improvement among subjects taking Pregabalin compared to Placebo.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percent of subjects improved from baseline to Week 16 BOCF for Pregabalin versus placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis represents the percent of subjects improved, also from 0 to 100. The solid line shows data for Pregabalin, and the dotted line shows data for placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.